Medication info

Sitagliptin Metformin Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›505mg / 1 tablet
Manufacturer / importer
Dongkuk Pharm Co., Ltd.
Appearance
Bright pink oval film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200616 · Approved 2022.02.08 · Insurance code 653405190

Summary

Main use
Improvement of glycemic control in type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use 2. Patients Who Must Not Receive This Drug). 2. Patients receiving metformin treatment: For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's existing metformin dose. Patients switching to this drug from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients Who Must Not Receive This Drug).

Ingredients

Manufacturer
Dongkuk Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes

  • Difficulty in controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used to help control blood sugar in patients with type 2 diabetes. It is administered in conjunction with dietary and exercise therapy, and can be taken by individuals who have not previously received diabetes medication treatment. If blood sugar control is insufficient with monotherapy using Metformin or Sitagliptin, this medication can be either substituted for or used in combination. It can also be taken alongside Metformin when blood sugar control is inadequate during combination therapy with sulfonylurea, or Metformin with thiazolidinedione. If blood sugar control remains inadequate when using insulin and Metformin together, therapy can be augmented with this medication. It is utilized in various therapeutic situations to improve blood sugar control.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use 2. Patients Who Must Not Receive This Drug). 2. Patients receiving metformin treatment: For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's existing metformin dose. Patients switching to this drug from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients Who Must Not Receive This Drug).

Precautions

This medication contains Sitagliptin and Metformin, and is used in the treatment of diabetes. Severe hypersensitivity reactions may occur while taking this medication, so if symptoms such as rash, hives, or difficulty breathing arise, discontinue use immediately and consult a physician. Acute pancreatitis has been reported, so if abdominal pain, vomiting, or severe abdominal discomfort occur, inform healthcare professionals immediately. This medication should not be used in cases of severe renal impairment or conditions that may affect kidney function such as acute heart failure, acute myocardial infarction, or severe infection. Before and after examinations using iodinated contrast agents, the administration of this medication should be discontinued, and it can only be resumed once normal kidney function is confirmed. It is safer not to take this medication during pregnancy or if pregnancy is possible, and it is not recommended for nursing mothers. Elderly patients are at a higher risk for decreased renal function, so kidney function should be regularly monitored and dosage adjusted accordingly. This medication can cause a rare but serious side effect called lactic acidosis, so if symptoms like sudden muscle pain, weakness, difficulty breathing, or abdominal pain occur, inform your doctor immediately. There is also a risk of hypoglycemia, especially when used in conjunction with insulin or sulfonylureas, so blood sugar levels should be carefully monitored. Alcohol may increase the risk of side effects from this medication, so excessive drinking should be avoided while taking it. Medication should be discontinued for a period before and after surgery, and it can be resumed only after the patient's condition stabilizes and kidney function is verified as normal. Regular blood tests and kidney function tests should be conducted while taking this medication, and periodic monitoring of vitamin B12 levels is recommended. Lastly, if any new symptoms or adverse reactions arise during treatment with this medication, consult healthcare professionals immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 21 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • elevated liver enzymes
  • acute kidney failure
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • dermatitis
  • anorexia
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture exposure, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Bright pink oval film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.